Form 4: 2seventy bio CEO William Baird III Reports Disposal of Shares and Options Following Merger with Bristol-Myers Squibb

William Baird III, CEO of 2seventy bio, reports the disposal of shares and stock options due to the merger with Bristol-Myers Squibb, where shares were acquired for $5.00 each.

Summary

• This Form 4 filing reports the changes in beneficial ownership of 2seventy bio, Inc. (TSVT) by CEO William Baird III following the merger with Bristol-Myers Squibb Company.
• The merger, effective May 13, 2025, involved Bristol-Myers Squibb acquiring all outstanding shares of 2seventy bio for $5.00 per share.
• As a result of the merger, Baird disposed of 1,002,825 shares of common stock and 118,209 shares of common stock.
• Additionally, outstanding restricted stock units (RSUs) became fully vested and were converted into the right to receive $5.00 per share.
• Stock options with an exercise price less than $5.00 were also converted into the right to receive the difference between $5.00 and the exercise price.
• Stock options with an exercise price equal to or greater than $5.00 were cancelled for no consideration.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a clear exit strategy for shareholders at a defined price. The cancellation of some options is a negative, but overall the merger is a positive event for shareholders.

Positives

• Shareholders received $5.00 per share as part of the merger agreement.
• RSUs were fully vested and converted into cash.
• Option holders with options below the merger price received the difference in cash.

Negatives

• Stock options with an exercise price equal to or greater than $5.00 were cancelled for no consideration.

Future Outlook

The company is now a wholly-owned subsidiary of Bristol-Myers Squibb.

Industry Context

This merger reflects a trend of larger pharmaceutical companies acquiring smaller biotech firms to expand their pipelines and capabilities, particularly in specialized areas like cell and gene therapy.

Comparison to Industry Standards

• Mergers in the biotech industry often involve a premium paid over the existing share price to incentivize shareholder approval.
• The $5.00 per share acquisition price needs to be compared to the trading price of TSVT prior to the announcement to assess the premium received.
• Comparable transactions in the cell and gene therapy space can provide benchmarks for valuation multiples and deal structures.

Stakeholder Impact

• Shareholders received $5.00 per share.
• Employees may experience changes as the company integrates into Bristol-Myers Squibb.
• Customers and partners may see changes in product development and commercialization strategies.

Key Dates

Keywords

merger, acquisition, 2seventy bio, Bristol-Myers Squibb, TSVT, William Baird III, Form 4, beneficial ownership, stock options, RSUs